Cardiovascular disease is the number one killer of women over 25 in the United States. Females account for 50.9% of the total US population and 63.1% of participants in National Institute of Health funded clinical research trials. However, female representation is lowest in studies for heart failure (29%), coronary artery disease (25%) and hyperlipidemia (28%) while females account for 51% of all individuals with heart failure, 46% for coronary heart disease, and 49% of those diagnosed with hyperlipidemia. Enrollment of woman in cardiovascular trials has increased over time, but remains low relative to their overall representation of the disease population as noted in a 2010 study titled “Representation of women in randomized clinical trials of cardiovascular disease prevention.”